Single-cell commercial leader Simone Günther, US biotechveteran Sandy Zweifach, and Werner Lanthaler (Wlanholding) join to guideMyllia's next phase of growth
Vienna, Austria – October 8, 2026 – MylliaBiotechnology, a specialist in high-content CRISPR screens in primary humancells, today announced the formation of its Board. The new governance body willoversee and advise Myllia's management team, led by co-founders Dr. ThomasMoser (CEO) and Dr. Tilmann Buerckstuemmer (CSO). The Board comprises SandyZweifach as Chair, Dr. Simone Günther, and Dr. Werner Lanthaler
The Board is formed at a time of strong momentum for Myllia.Building on its single-cell CRISPR screening platform (Perturb-seq), thecompany has launched VISTA™, the first platform for genome-wide CRISPR screensin primary human cells, and has added multimodal optical pooled screening toits offering. At the same time, demand is rising for large, human-relevantperturbation datasets to train AI models of cell biology – an area whereMyllia's primary-cell data are increasingly sought after by pharma and biotechpartners.
About the Board members
Dr. Simone Günther brings more than 20 years ofcommercial leadership in life science tools and molecular diagnostics companiesacross Europe, the Middle East and Africa. Most recently, she led theSingle-Cell MultiOmics business in EMEA at BD Biosciences (now part of Waters),with full P&L responsibility for the BD Rhapsody™ portfolio. At BD, shebuilt the European single-cell multiomics commercial team from the ground upand later led the EMEA Scientific & Application Support organization ofmore than 90 people. Earlier roles include Business & Medical Lead forMolecular Diagnostics at QIAGEN and Director Market Development & BusinessStrategy at Thermo Fisher Scientific (Life Technologies). Simone holds a PhD inBiology from the University of Karlsruhe and completed a postdoctoralfellowship at Yale University.
Sandy Zweifach has more than 35 years of experiencein the life sciences industry, with deep relationships across pharma R&D,business development and the investment community. He has served as CEO orPresident of five companies, raised more than $750 million in capital and lednumerous M&A and licensing transactions. Most recently, he led Imidomics,Inc. as their CEO and successfully sold the core business to UCB. Sandy is aSenior Advisor to Bioqube Ventures and holds several board positions, includingExecutive Chair of Paradox Immunotherapeutics and non-executive director ofCompugen. He holds an MS in Human Physiology from the University of California,Davis, and a BA in Biology from the University of California, San Diego.
Dr. Werner Lanthaler served as CEO of Evotec SE from2009 to 2024. Before Evotec, he was CFO of Intercell AG, where he led Austria'sfirst VC-backed biotech IPO, and earlier worked with McKinsey & Company.Werner is CEO of FairJourney Biologics and founder of WLan Holding, aVienna-based investment company focused on life sciences and sustainability. Heserves on several boards, including InSphero, HAL Allergy, Proxygen, Elucidata.He holds a PhD in Business Administration from WU Vienna and a Master of PublicAdministration from Harvard University.
Quotes
“With Simone, Sandy, and Werner, we gain a Board thatcombines exactly the experience we need for our next stage: building a globaldiscovery business, commercializing cutting-edge single-cell technology, andpartnering with pharma in the US and Europe," said Dr. Thomas Moser,CEO and co-founder of Myllia Biotechnology. "We look forward to theirguidance as we scale our platform and our partnerships."
"Functional genomics in primary human cells and thedata Myllia generates are extremely value inputs for AI-driven drug discovery,”said Sandy Zweifach. "I am delighted to support a Vienna-basedteam that has built a truly differentiated platform."
About Myllia Biotechnology
Myllia Biotechnology is a Vienna-based company that combinesCRISPR perturbation screens with single-cell and image-based readouts inprimary human cells to deliver mechanistic, human-relevant insights for drugdiscovery. Its end-to-end platform supports CRISPR knockout, interference andactivation screens in immune, metabolic, renal and cancer cell models, enablingtarget discovery, mode-of-action studies and the generation of AI-readyperturbation datasets. Myllia partners with pharmaceutical and biotechcompanies worldwide. For more information, visit myllia.com.
Media contact
Tilmann Buerckstuemmer
Email [email protected]
Phone +4369911431964
Myllia Biotechnology GmbH
Am Kanal 27
1110 Wien
Austria
Photos
From left to right: Sandy Zweifach, Simone Günther, Werner Lanthaler